Showing 2,041 - 2,060 results of 5,570 for search '"oncology"', query time: 0.07s Refine Results
  1. 2041
  2. 2042
  3. 2043
  4. 2044
  5. 2045
  6. 2046

    Efficacy and safety of immune checkpoint inhibitors in elderly patients with advanced non-small cell lung cancer: a systematic review and meta-analysisResearch in context by Jiacheng Yao, Sihan Li, Lu Bai, Jun Chen, Chengbo Ren, Tingting Liu, Jingping Qiu, Jun Dang

    Published 2025-03-01
    “…In real-world studies, the pooled median OS of ICIs were 11.8 months (95% CI: 11.2–12.4); Eastern Cooperative Oncology Group (EOCG) score, histological type, PD-L1 status, with immune-related adverse events (irAEs), and treatment mode were predictive for OS; rates of irAEs and discontinuation were numerically higher for combination therapy vs. monotherapy. …”
    Get full text
    Article
  7. 2047
  8. 2048
  9. 2049
  10. 2050
  11. 2051
  12. 2052
  13. 2053
  14. 2054
  15. 2055

    Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose? by Marka Crittenden, Sandra Demaria, C Norman Coleman, Jonathan Schoenfeld, Arta Monjazeb, Samir Khleif, Seema Gupta, Andrew Sikora, Zachary Morris, Chandan Guha, Stephen Shiao, Silvia Chiara Formenti, Bhadrasain Vikram, Mansoor M Ahmed

    Published 2021-04-01
    “…Radiation oncologists and immunologists convened a virtual consensus discussion to identify current deficiencies, challenges, pitfalls and critical gaps when combining radiotherapy with immunotherapy and making recommendations to the field and advise National Cancer Institute on new directions and initiatives that will help further development of these two fields.This commentary aims to raise the awareness of this complexity so that the need to study radiation dose, fractionation, type and volume is understood and valued by the immuno-oncology research community. Divergence of approaches and findings between preclinical studies and clinical trials highlights the need for evaluating the design of future clinical studies with particular emphasis on radiation dose and fractionation, immune biomarkers and selecting appropriate end points for combination radiation/immune modulator trials, recognizing that direct effect on the tumor and potential abscopal effect may well be different. …”
    Get full text
    Article
  16. 2056
  17. 2057
  18. 2058
  19. 2059
  20. 2060